30-Second Takeaway
- AID systems meaningfully improve glycemia and modestly reduce hypoglycemia in insulin-treated type 2 diabetes, without weight gain.
- In adults ≥65, GLP-1 RAs and SGLT2 inhibitors show safer profiles than sulfonylureas, with SGLT2i carrying higher DKA risk.
- Early CKM data reinforce SGLT2 inhibitors as uniquely protective for ESRD and survival versus other first-line antidiabetic agents.
- CGM in pregnancy lowers NICU admissions but increases SGA risk, underscoring the need to individualize glycemic targets.
- Stress hyperglycemia in acute pancreatitis strongly predicts early-onset diabetes, defining a high-yield group for post-discharge screening.
Week ending April 11, 2026
New data on diabetes technologies and therapeutics: refining technology adoption, drug selection, and risk stratification
Automated insulin delivery substantially improves glycemia in insulin-treated type 2 diabetes
This meta-analysis of nine studies (1,530 participants) evaluated automated insulin delivery (AID) systems in insulin-treated type 2 diabetes using CGM outcomes. AID increased time in range by about 16 percentage points and lowered time above range, mean glucose, and HbA1c by roughly 1.3 percentage points. Time below range fell modestly, indicating improved hypoglycemia safety despite tighter control, and body weight and BMI were unchanged. Only three randomized trials and heterogeneous designs limit certainty, but findings support AID use in appropriate insulin-treated type 2 diabetes patients.
GLP-1 RAs and SGLT2 inhibitors show safer profiles than sulfonylureas in older adults
This multinational cohort included 1.8 million adults ≥65 years starting second-line agents, comparing 18 safety outcomes across four drug classes. GLP-1 receptor agonists and SGLT2 inhibitors were associated with lower hypoglycemia and hyperkalemia risks than sulfonylureas. GLP-1 receptor agonists also had lower peripheral edema risk than DPP-4 inhibitors, supporting their use over DPP-4 inhibitors when feasible. SGLT2 inhibitors carried a higher diabetic ketoacidosis risk than GLP-1 receptor agonists and sulfonylureas, requiring counseling and monitoring in susceptible patients.
GLP1R and GIPR variants predict weight loss and GI side effects with GLP-1–based therapy
This genome-wide association study examined 27,885 individuals reporting weight loss and side effects on GLP-1 receptor agonists, including semaglutide and tirzepatide. A missense GLP1R variant was linked to greater weight loss efficacy, with about 0.76 kg more loss per effect-allele copy. Variants in GLP1R and GIPR were associated with GLP-1–related nausea or vomiting, with the GIPR signal observed only in tirzepatide users. A prediction model incorporating these variants stratified patients by expected efficacy and side-effect risk, supporting future pharmacogenomic incretin tailoring.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.